New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:56 EDTPCYC, GILDDeutsche Bank biopharma nalysts hold an analyst/industry conference call
Analysts, along with a Key Opinion Leader of Chronic Lymphocytic Leukemia, provide a review of Pharmacyclics (PCYC) and Gilead Sciences (GILD) data presented at the recently held ASCO Annual Meeting on an Analyst/Industry conference call to be held on June 9 at 10:30 am.
News For PCYC;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2015
14:08 EDTPCYCEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information
07:07 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 21, 2015
16:00 EDTGILDOptions Update; April 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1c to 21.53 Option volume leaders: AAPL TSLA TWTR GILD FB PBR AMZN C KMI KO VZ MCD according to Track Data.
13:34 EDTGILDGilead paying premium to buy Vertex not warranted right now, says Maxim
After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.
12:33 EDTGILDOn The Fly: Top stock stories at midday
Subscribe for More Information
12:21 EDTGILDVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
10:00 EDTGILDGilead spikes higher, levels to watch
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:14 EDTGILDGilead should buy Vertex, says Bernstein
Subscribe for More Information
06:58 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 20, 2015
14:32 EDTPCYCPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:05 EDTPCYCPharmacyclics reports positive data suggesting ibrutinib is an effective option
Ibrutinib data presented yesterday by Pharmacyclics at the American Association for Cancer Research, or AACR, Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft mice. These early, pre-clinical data show ibrutinib was associated with potent anti-fibrotic activity and longer survival in the treated mice. PDAC is a type of pancreatic cancer that is typically characterized by a fibro-inflammatory reaction, which makes PDAC a difficult disease to treat with current therapies. These data were also published in the April 15th edition of Cancer Research. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech.
08:47 EDTPCYCPharmacyclics announces positive results from PCYC-1102 study
Pharmacyclics announced that IMBRUVICA follow-up data in treatment-naive, or TN, and relapsed/refractory patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, or CLL and SLL respectively, demonstrated that, with up to 45 months of follow-up, the 94 patients who received IMBRUVICA 420 mg experienced a 91% overall response rate, or ORR, and 14% of all patients achieved a complete response. These data are an analysis of outcomes from the Phase I/IIb study, or PCYC-1102, and the ongoing extension study and were presented in an oral presentation at the American Association of Cancer Research.
07:20 EDTGILDAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 17, 2015
16:50 EDTPCYCAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
April 13, 2015
16:01 EDTGILDOptions Update; April 13, 2015
Subscribe for More Information
14:07 EDTPCYCEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use